Inhibitors of hepatitis C virus polymerase: Synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines

Journal of Medicinal Chemistry

Volumn 52, Issue 6, 2009, Pages 1659-1669

  Wagner, Rolf ^a   Larson, Daniel P ^a   Beno, David W A ^a   Bosse, Todd D ^a   Darbyshire, John F ^a,b   Gao, Yi ^a   Gates, Bradley D ^a   He, Wenping ^a,c   Henry, Rodger F ^a   Hernandez, Lisa E ^a   Hutchinson, Douglas K ^a   Jiang, Wen W ^a,d   Kati, Warren M ^a   Klein, Larry L ^a,e   Koev, Gennadiy ^a   Kohlbrenner, William ^a   Krueger, A Chris ^a   Liu, Jinrong ^a   Liu, Yaya ^a   Long, Michelle A ^a   Maring, Clarence J ^a   Masse, Sherie V ^a   Middleton, Tim ^a   Montgomery, Debra A ^a   Pratt, John K ^a   Stuart, Patricia ^a   Molla, Akhteruzzaman ^a   Kempf, Dale J ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b Nycomed   (Germany)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d MIDWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZINE DERIVATIVE; DNA DIRECTED DNA POLYMERASE ALPHA; SODIUM 2 (7 METHANESULFONYLAMINO 1,1 DIOXO 1,4 DIHYDRO 1LAMBDA 6 BENZO[1,2,4]THIADIAZIN-3-YL) 4 METHYL 4 (3 METHYL BUTYL) 3 OXO 3,4 DIHYDRO NAPHTHALEN 1 OLATE; SODIUM 4 (3,3 DIMETHYL BUTYL) 2 (7 METHANESULFONYLAMINO 1,1 DIOXO 1,4 DIHYDRO 1LAMBDA 6 BENZO[1,2,4]THIADIAZIN-3-YL) 4 METHYL 3 OXO-3,4 DIHYDRO NAPHTHALEN 1 OLATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; RAT; REPLICON;

ANIMALS; BENZOTHIADIAZINES; BIOLOGICAL AVAILABILITY; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; HALF-LIFE; HEPACIVIRUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 64349095594     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8010965     Document Type: Article

References (50)

1. Choo, Q.; Kuo, G.; Weiner, A.; Overby, L.; Bradley, D.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science 1989, 244, (4902), 359-362.
2. (b) Kuo, G.; Choo, Q.; Alter, H.; Gitnick, G.; Redeker, A.; Purcell, R.; Miyamura, T.; Dienstag, J.; Alter, M.; Stevens, C. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989, 244 (4902), 362-364.
3. Cohen, J. Public health effort unwittingly spread HCV. Science 1999, 285 (5424), 27.
4. Prince, A. M.; Grady, G. F.; Hazzi, C.; Brotman, B.; Kuhns, W. J.; Levine, R. W.; Millian, S. J. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis B virus. Lancet 1974, 2 (7875), 241-246.
5. (b) Koretz, R. L.; Suffin, S. C.; Gitnick, G. L. Post-transfusion chronic liver disease. Gastroenterology 1976, 71, 797-803.
6. (c) Mathiesen, L. R.; Skinhoj, P.; Hardt, F.; Nielsen, J. O.; Sloth, K.; Zoffmann, H. Epidemiology and clinical characteristics of acute hepatitis types A, B, and non-A non-B. Scand J. Gastroen-terol. 1979, 14 (7), 849-856.
7. (d) Koretz, R. L.; Stone, O.; Gitnick, G. L. The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterology 1980, 79, 893-898.
8. (e) Kryger, P.; Aldershvile, J.; Christoffersen, P.; Hardt, F.; Juhl, E.; Mathiesen, L. R.; Nielsen, J. O.; Poulsen, H. Acute non-A, non-B hepatitis- clinical, epidemiological and histological characteristics. Scand. J. Infect. Dis. 1980, 12, 165-169.
9. (f) Mathiesen, L. R.; Hardt, F.; Dietrichson, O.; Purcell, R. H.; Wong, D.; Skinhoj, P.; Nielsen, J. O.; Zoffmann, H.; Iversen, K. The role of acute hepatitis type A, B, and non-A non-B in the development of chronic active liver disease. Scand. J. Gastroenterol. 1980, 15 (1), 49-54.
10. Poynard, T.; Bedossa, P.; Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349, 825-832.
11. (b) Yatsuhashi, H.; Yano, M. Towards control of hepatitis C in the Asia-Pacific region-Natural history of chronic hepatitis C. J. Gastroenterol. Hepatol. 2000, 15 (Suppl.), E111-E116.
12. (c) Pearlman, B. L. Hepatitis C Infection: A Clinical Review. South. Med. J. 2004, 97 (4), 364-373.
13. (d) Ascione, A.; Tartaglione, T.; Giuseppe Di Costanzo, G. Natural history of chronic hepatitis C virus infection. Dig. Liver Dis. 2007, 39 (Suppl 1), S4-S7.
14. Kilpe, V. E.; Krakauer, H.; Wren, R. E. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993, 56, 554-561.
15. (b) Alter, M. J. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997, 1, 559-568.
16. (c) Primary Liver Disease of Liver Transplant Recipients 1991 and 1992 (From the UNOS Scientific Registry). UNOS Update 1993, 9, 27.
17. Rao, K. V.; Anderson, R. C. Long-term results and complications in renal transplant recipients. Observations in the second decade. Transplantation 1988, 45, 45-52.
18. Wise, M.; Bialek, S.; Finelli, L.; Bell, B. P.; Sorvillo, F. Changing trends in hepatitis C-related mortality in the United States 1995- 2004. Hepatology 2008, 47 (4), 1128-1135.
19. Davis, G. L.; Albright, J. E.; Cook, S. F.; Rosenberg, D. M. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant. 2003, 9 (4), 331-338.
20. (b) National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997, 26 (Suppl. 1), 2S -10S.
21. Deuffic-Burban, S.; Poynard, T.; Sulkowski, M. S.; Wong, J. B. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J. Vir. Hepatitis 2007, 14, 107-115.
22. Kato, N. Genome of human hepatitis c virus (HCV): Gene organization, sequence diversity, and variation. Microbiol. Comp. Genomics 2000, 5 (3), 129-151.
23. (b) Zein, N. N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 2000, 223-235.
24. (c) Ramadori, G.; Meier, V. Hepatitis C virus infection: 10 years after the discovery of the virus. Eur. J. Gastroenterol. Hepatol. 2001, 13, 465-471.
25. Malnick, S. D. H.; Beergabel, M.; Lurie, Y. Treatment of chronic hepatitis C virus infection. Ann. Pharmacother. 2000, 34 (10), 1156-1164, see also the reference of footnote 4 authored by Pearlman, B. L.
26. Hoeroldt, B.; Haydon, G.; O'Donnell, K.; Dudley, T.; Nightingale, P.; Mutimer, D. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int. 2006, 26, 650-659.
27. (b) Manns, M. P.; Wedemeyer, H.; Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55, 1350-1359.
28. (c) Mallolas, J.; Laguno, M. Pegylated IFN-a2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV. Expert Rev. Anti-Infect. Ther. 2008, 6 (3), 281-289.
29. Bartenschlager, R. Candidate targets for hepatitis C virus-specific antiviral therapy. Intervirology 1997, 40 (5-6), 378-393.
30. Lohmann, V.; Korner, F.; Herian, U.; Bartenschlager, R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymic activity. J. Virol. 1997, 71 (11), 8416-8428.
31. (b) Lohmann, V.; Roos, A.; Korner, F.; Koch, J. O.; Bartenschlager, R. Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology 1998, 249 (1), 108-118.
32. (c) Lohmann, V.; Roos, A.; Korner, F.; Koch, J. O.; Bartenschlager, R. Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J. Vir. Hepatitis 2000, 7 (3), 167-174.
33. (d) Ivashkina, N.; Wolk, B.; Lohmann, V.; Bartenschlager, R.; Blum, H. E.; Penin, F.; Moradpour, D. The hepatitis C virus RNA-dependent RNA polymerase membrane insertion sequence is a transmembrane segment. J. Virol. 2002, 76 (24), 13088-13093.
34. (e) Moradpour, D.; Brass, V.; Bieck, E.; Friebe, P.; Gosert, R.; Blum, H. E.; Barten-schlager, R.; Penin, F.; Lohmann, V. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J. Virol. 2004, 78 (23), 13278-13284.
35. (a) Parfieniuk, A.; Jaroszewicz, J.; Flisiak, R. Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol. 2007, 13 (43), 5673-5681.
36. (b) Liu-Young, G.; Kozal, M. J. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDs 2008, 22 (6), 449-457.
37. (c) Beaulieu, P. L. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr. Opin. Invest. Drugs 2007, 8 (8), 614-634.
38. See example 432c in Pratt, J. K.; Betebenner, D. A.; Donner, P. L.; Green, B. E.; Kempf, D. J.; McDaniel, K. F.; Maring, C. J.; Stoll, V. S.; Zhang, R. Preparation of1,1-dioxido-4H-1,2,4-benzothiadiazines as hepatitis C polymerase inhibitors and anti-infective agents U.S. Patent 2004087577, 2004.
39. Bosse, T. D.; Larson, D. P.; Wagner, R.; Hutchinson, D. K.; Rockway, T. W.; Kati, W. M.; Liu, Y.; Masse, S.; Middleton, T.; Mo, H.; Montgomery, D.; Jiang, W.; Koev, G.; Kempf, D. J.; Molla, A. Synthesis and SAR of novel 1,1-dialkyl-2(1 H)-naphthalenones as potent HCV polymerase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18 (2), 568-570.
40. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Kraeusslich, H.-G.; Mizokami, M.; Bartenschlager, R.; Liang, T. J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11 (7), 791-796.
41. (b) Zhong, J.; Gastaminza, P.; Cheng, G.; Kapadia, S.; Kato, T.; Burton, D. R.; Wieland, S. F.; Uprichard, S. L.; Wakita, T.; Chisari, F. V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (26), 9294-9299.
42. Lohman, V.; Korner, F.; Koch, J.; et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285 (5424), 110-113.
43. (b) Blight, K. J.; Kolykhalov, A. A.; Rice, C. M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290 (5498), 1972-1974.
44. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Boes, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.; Rancourt, J.; Sentjens, R. E.; George, R.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426 (6963), 186-189.
45. See compound 13 in:(a) Krueger, A. C.; Madigan, D. L.; Green, B. G.; Hutchinson, D. K.; Jiang, W. W.; Kati, W. M.; Liu, Y.; Maring, C. J.; Masse, S. V.; McDaniel, K. F.; Middleton, T. R.; Mo, H.; Molla, A.; Montgomery, D.; Ng, T. I.; Kempf, D. J. Inhibitors of HCV NS5B polymerase: synthesis and structure activity relationships of unsymmetrical 1-hydroxy-4,4-dialkyl-3-oxo-3,4- dihydronapthalene benzothiadiazine derivatives. Bioorg. Med. Chem. Lett. 2007, 17, 2289-2292.
46. Chen, C-M.; He, Y.; Lu, L.; Lim, H. B.; Tripathi, R. L.; Middleton, T.; Hernandez, L. E.; Beno, D.W. A.; Long, M. A.; Kati, W. M.; Bosse, T. D.; Larson, D. P.; Wagner, R.; Lanford, R. E.; Kohlbrenner, W. E.; Kempf, D. J.; Pilot-Matias, T. J.; Molla, A. Activity of a potent hepatitis C virus polymerase inhibitor in the himpanzee model. Antimicrob.AgentsChemother- 2007, 51, 4290-4296.
47. (23)See example 3 Part A in: Wagner, R.; Donner, P. L.; Kempf, D. J.; Maring, C. J.; Stoll, V. S.; Pu, Y. Preparation of fused thiadiazines as hepatitis C virus (HCV) polymerase inhibitors. Patent WO 2008 011337, 2008.
48. (24)See example 414a in Pratt, J. K.; Betebenner, D. A.; Donner, P. L.; Green, B. E.; Kempf, D. J.; McDaniel, K. F.; Maring, C. J.; Stoll, V. S.; Zhang, R. Preparation of 1,1-dioxido-4H-1,2,4-benzothiadiazines as hepatitis C polymerase inhibitors and anti-infective agents. Patent WO 2004 0411818, 2004.
49. Yi, M.; Lemon, S. M. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J. Virol. 2004, 78, 7904-7915.
50. Pauwels, R. J.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; DeClerq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.